Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

被引：0
|
作者：
M Zia Sadique
Richard Grieve
David A Harrison
Brian H Cuthbertson
Kathryn M Rowan
机构：
[1] London School of Hygiene and Tropical Medicine,Department of Health Services Research and Policy, WC1H 9SH
[2] Research Centre,Intensive Care National Audit &WC1H 9HR
[3] Sunnybrook Health Sciences Centre,Department of Critical Care Medicine, M4N 3M5
来源：
Critical Care | / 15卷
关键词：
Severe Sepsis; Critical Care; Additional Data File; Acute Hospital; Critical Care Unit;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in Sweden
    Hjelmgren, J
    Ragnarson, TG
    Persson, U
    Davis, A
    Finnern, HW
    Myren, KJ
    INTENSIVE CARE MEDICINE, 2003, 29 : S94 - S94
  • [22] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Schneider, H
    Chinn, C
    Clouth, J
    Burchardi, H
    INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [23] Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in the UK
    Davies, A
    Hutton, J
    Ridley, S
    Chinn, C
    Barber, B
    INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [24] The development of drotrecogin alfa (activated) for the treatment of severe sepsis
    Macias, WL
    Yan, SB
    Grinnell, BW
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2004, 27 (05): : 360 - 370
  • [25] Readministration of drotrecogin alfa (activated) in an adult with severe sepsis
    Scipione, Marco R.
    Nogid, Boris
    Davanos, Evangelia
    DiGregorio, Robert V.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (18) : 1711 - 1715
  • [26] Timing of drotrecogin alfa (activated) treatment in severe sepsis
    Choi, Goda
    de Pont, Anne-Cornelie J. M.
    Schultz, Marcus J.
    CRITICAL CARE, 2006, 10 (04):
  • [27] Timing of drotrecogin alfa (activated) treatment in severe sepsis
    Goda Choi
    Anne-Cornélie JM de Pont
    Marcus J Schultz
    Critical Care, 10
  • [28] Hemorrhagic risk of (activated) drotrecogin alfa in severe sepsis
    Perrotin, D
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2003, 22 : 16 - 19
  • [29] DROTRECOGIN ALFA (ACTIVATED) IN REAL-LIFE CLINICAL PRACTICE FOR MANAGEMENT OF SEVERE SEPSIS IN SURGICAL PATIENTS
    Lopez Sanchez, F.
    Mas-Serrano, P.
    Caturla Such, J.
    Mignini, M.
    Navarro, J.
    INTENSIVE CARE MEDICINE, 2010, 36 : S193 - S193
  • [30] A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial
    Wheeler, Arthur
    Steingrub, Jay
    Schmidt, Gregory A.
    Sanchez, Philip
    Jacobi, Judith
    Linde-Zwirble, Walter
    Bates, Becky
    Qualy, Rebecca L.
    Woodward, Brad
    Zeckel, Michael
    CRITICAL CARE MEDICINE, 2008, 36 (01) : 14 - 23
12345